Filing Flows › Ligand Pharmaceuticals (LGND) › R&D spending
Ligand Pharmaceuticals (LGND) R&D spending by quarter
Ligand Pharmaceuticals' R&D spending was $2.8M in Q3 2026 (third quarter 2026), -81% from Q2 2026. Over the last 7 quarters it ranged from $2.1M (Q1 2026) to $50.1M (Q1 2025).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $2.8M | -81% | -87% |
| Q2 2026 | $14.7M | +583% | +123% |
| Q1 2026 | $2.1M | -39% | -96% |
| Q4 2025 | $3.5M | -83% | — |
| Q3 2025 | $21.0M | +220% | — |
| Q2 2025 | $6.6M | -87% | — |
| Q1 2025 | $50.1M | — | — |
Q3 2026 at a glance
Ligand Pharmaceuticals, Q3 2026: revenue $78.7M (-32% year over year), operating margin -20.0%, net loss $28.5M, operating cash flow −$27.6M. The chart follows the revenue to costs, profit and cash.
Questions
What is Ligand Pharmaceuticals' R&D spending?
Ligand Pharmaceuticals' R&D spending was $2.8M in Q3 2026 (third quarter 2026), -81% from Q2 2026.
How has Ligand Pharmaceuticals' R&D spending changed?
Over the last 7 quarters it ranged from $2.1M (Q1 2026) to $50.1M (Q1 2025).
Q3 2026 results → · How Ligand Pharmaceuticals makes money →